Contact Us
Drug Search Results
More Filters [+]

PPD-10558

Alternative Names: ppd-10558, ppd10558, ppd 10558
Latest Update: 2011-12-22
Latest Update Note: Clinical Trial Update

Product Description

Furiex was developing ppd-10558, an oral HMG-CoA Inhibitor for Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-associated Myalgia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01279590)

Mechanisms of Action: HMG-CoA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Furiex
Company Location: MORRISVILLE NC 27560
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PPD-10558

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hypercholesterolemia|Hyperlipidemia|Myalgia|Hyperlipoproteinemias

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PPD10558-010

P2

Completed

Myalgia|Hyperlipidemia|Hyperlipoproteinemias|Hypercholesterolemia

2011-11-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions